


AMENDMENTS TO THE CLAIMS

1. - 7. (canceled)

8. (currently amended) A pharmaceutical composition for the ~~treatment or~~ prevention of disease conditions mediated by 5-HT<sub>4</sub> receptor activity, in a mammalian subject, which comprises a therapeutically effective amount of a ~~compound of Claim 1~~ a compound of the formula (I):



or the pharmaceutically acceptable salts thereof wherein

R<sup>1</sup> is hydrogen, halo or C<sub>1-6</sub> alkyl;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, mono- or di-(C<sub>1-5</sub>)alkyl amino, amino(C<sub>1-5</sub>)alkyl or hydroxy(C<sub>1-5</sub>)alkyl; or R<sup>2</sup> and R<sup>3</sup> taken together with the nitrogen atom to which they are attached may form substituted or non-substituted nitrogen-containing heterocyclic;

R<sup>4</sup> is hydrogen, halo, C<sub>1-8</sub> acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C<sub>1-6</sub>)alkyl, or substituted or non-substituted heterocyclic;

R<sup>5</sup> is hydrogen, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-8</sub> acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C<sub>1-6</sub>)alkyl, or substituted or non-substituted heterocyclic;


R<sup>6</sup> is hydrogen, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy (C<sub>1-6</sub>)alkyl;

X is NR<sup>9</sup> wherein R<sup>9</sup> is hydrogen or C<sub>1-6</sub> alkyl; and

Y is (CR<sup>7</sup>R<sup>8</sup>)<sub>n</sub> wherein R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or C<sub>1-6</sub> alkyl, and n is an integer from 0 to 5.;

and a pharmaceutically acceptable carrier.

9. (currently amended) A pharmaceutical composition for the ~~treatment or~~ prevention of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, upper gut motility disorder, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageal disease, ~~nausea~~ nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischaemic stroke, anxiety or cardiovascular disorder, which comprises a therapeutically effective amount of ~~a compound of Claim 1~~ a compound of the formula (I):



or the pharmaceutically acceptable salts thereof wherein

R<sup>1</sup> is hydrogen, halo or C<sub>1-6</sub> alkyl;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, mono- or di-(C<sub>1-5</sub>)alkyl amino, amino(C<sub>1-5</sub>)alkyl or hydroxy(C<sub>1-5</sub>)alkyl; or R<sup>2</sup> and R<sup>3</sup> taken together with the nitrogen atom to which they are attached may form substituted or non-substituted nitrogen-containing heterocyclic;

R<sup>4</sup> is hydrogen, halo, C<sub>1-8</sub> acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C<sub>1-6</sub>)alkyl, or substituted or non-substituted heterocyclic;

R<sup>5</sup> is hydrogen, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-8</sub> acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C<sub>1-6</sub>)alkyl, or substituted or non-substituted heterocyclic;


R<sup>6</sup> is hydrogen, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy (C<sub>1-6</sub>)alkyl;

X is NR<sup>9</sup> wherein R<sup>9</sup> is hydrogen or C<sub>1-6</sub> alkyl; and

Y is  $(CR^7R^8)_n$  wherein  $R^7$  and  $R^8$  are independently hydrogen or  $C_{1-6}$  alkyl, and n is an integer from 0 to 5;

and a pharmaceutically acceptable carrier.

**10.** (currently amended) A method for the ~~treatment~~ or prevention of disease conditions mediated by 5-HT<sub>4</sub> receptor activity, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a ~~compound according to Claim 1~~ a compound of the formula (I):



or the pharmaceutically acceptable salts thereof wherein

$R^1$  is hydrogen, halo or  $C_{1-6}$  alkyl;

$R^2$  and  $R^3$  are independently hydrogen,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, mono- or di-  
( $C_{1-5}$ )alkyl amino, amino( $C_{1-5}$ )alkyl or hydroxy( $C_{1-5}$ )alkyl; or  $R^2$  and  $R^3$  taken together with  
the nitrogen atom to which they are attached may form substituted or non-substituted  
nitrogen-containing heterocyclic;

$R^4$  is hydrogen, halo,  $C_{1-8}$  acyl, amino, amido, substituted or non-substituted aryl, substituted  
or non-substituted aryl( $C_{1-6}$ )alkyl, or substituted or non-substituted heterocyclic;


$R^5$  is hydrogen, halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-8}$  acyl, amino, amido,  
substituted or non-substituted aryl, substituted or non-substituted aryl( $C_{1-6}$ )alkyl, or  
substituted or non-substituted heterocyclic;

$R^6$  is hydrogen,  $C_{1-6}$  alkyl or  $C_{1-6}$  alkoxy ( $C_{1-6}$ )alkyl;

X is  $NR^9$  wherein  $R^9$  is hydrogen or  $C_{1-6}$  alkyl; and

Y is  $(CR^7R^8)_n$  wherein  $R^7$  and  $R^8$  are independently hydrogen or  $C_{1-6}$  alkyl, and n is an  
integer from 0 to 5.

11. (currently amended) A method for the ~~treatment or~~ prevention of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, upper gut motility disorder, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageal disease, ~~nausea~~ nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischaemic stroke, anxiety or cardiovascular disorder, which comprises administering to said subject a therapeutically effective amount of ~~a compound according to Claim 1~~ a compound of the formula (I):



or the pharmaceutically acceptable salts thereof wherein

R<sup>1</sup> is hydrogen, halo or C<sub>1-6</sub> alkyl;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, mono- or di-(C<sub>1-5</sub>)alkyl amino, amino(C<sub>1-5</sub>)alkyl or hydroxy(C<sub>1-5</sub>)alkyl; or R<sup>2</sup> and R<sup>3</sup> taken together with the nitrogen atom to which they are attached may form substituted or non-substituted nitrogen-containing heterocyclic;

R<sup>4</sup> is hydrogen, halo, C<sub>1-8</sub> acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C<sub>1-6</sub>)alkyl, or substituted or non-substituted heterocyclic;

R<sup>5</sup> is hydrogen, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-8</sub> acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C<sub>1-6</sub>)alkyl, or substituted or non-substituted heterocyclic;

R<sup>6</sup> is hydrogen, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy (C<sub>1-6</sub>)alkyl;

X is NR<sup>9</sup> wherein R<sup>9</sup> is hydrogen or C<sub>1-6</sub> alkyl; and

Y is  $(CR^7R^8)_n$  wherein  $R^7$  and  $R^8$  are independently hydrogen or  $C_{1-6}$  alkyl, and n is an integer from 0 to 5.

12. – 13. (canceled)